MedTrace Logo

Efficacy of Tadalafil/Solifenacin VS Tamsulosin/Solifenacin Combination Therapy for BPH/OAB

NCT05494567 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2022-08-10

No results posted yet for this study

Summary

The investigators will compare the efficacy and safety of tadalafil/solifenacin combination therapy versus tamsulosin/solifenacin combination therapy for the treatment of BPH/OAB in a randomized controlled trial (RCT).

Conditions

Interventions

DRUG

Tadalafil 5mg

patients with BPH/OAB will be treated with combination therapy of tadalafil plus solifenacin for 12 weeks in group 1

DRUG

Tamsulosin Hcl 0.4 mg

patients with BPH/OAB will be treated with combination therapy of tamsulosin plus solifenacin for 12 weeks in group 2

DRUG

solifenacin 10 mg

patients with BPH/OAB will be treated with combination therapy of tadalafil plus solifenacin in group 1 and tamsulosin plus solifenacin in group 2 for 12 weeks

Sponsors & Collaborators

  • Mansoura University

    lead OTHER

Principal Investigators

  • Mohammed Hegazy · Mansoura University

  • Ahmed Elhefnawy · Mansoura University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-08
Primary Completion
2022-08-31
Completion
2022-08-31

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05494567 on ClinicalTrials.gov